KR20230037549A - Brm 표적화 화합물 및 관련 사용 방법 - Google Patents

Brm 표적화 화합물 및 관련 사용 방법 Download PDF

Info

Publication number
KR20230037549A
KR20230037549A KR1020237000892A KR20237000892A KR20230037549A KR 20230037549 A KR20230037549 A KR 20230037549A KR 1020237000892 A KR1020237000892 A KR 1020237000892A KR 20237000892 A KR20237000892 A KR 20237000892A KR 20230037549 A KR20230037549 A KR 20230037549A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
groups
compound
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237000892A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 폴 콤즈
홍 린
필립 피티스
리앙 루
Original Assignee
프렐루드 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프렐루드 테라퓨틱스, 인코포레이티드 filed Critical 프렐루드 테라퓨틱스, 인코포레이티드
Publication of KR20230037549A publication Critical patent/KR20230037549A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
KR1020237000892A 2020-06-09 2021-06-09 Brm 표적화 화합물 및 관련 사용 방법 Pending KR20230037549A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036811P 2020-06-09 2020-06-09
US63/036,811 2020-06-09
PCT/US2021/036664 WO2021252666A1 (en) 2020-06-09 2021-06-09 Brm targeting compounds and associated methods of use

Publications (1)

Publication Number Publication Date
KR20230037549A true KR20230037549A (ko) 2023-03-16

Family

ID=76731093

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237000892A Pending KR20230037549A (ko) 2020-06-09 2021-06-09 Brm 표적화 화합물 및 관련 사용 방법

Country Status (16)

Country Link
US (2) US11702423B2 (https=)
EP (2) EP4161935B1 (https=)
JP (1) JP2023529908A (https=)
KR (1) KR20230037549A (https=)
CN (1) CN115867554B (https=)
AU (1) AU2021289730A1 (https=)
BR (1) BR112022025061A2 (https=)
CA (1) CA3185888A1 (https=)
DK (1) DK4161935T3 (https=)
ES (1) ES3034380T3 (https=)
FI (1) FI4161935T3 (https=)
IL (1) IL298933B1 (https=)
MX (1) MX2022015732A (https=)
PL (1) PL4161935T3 (https=)
PT (1) PT4161935T (https=)
WO (1) WO2021252666A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
EP4081308A4 (en) 2019-12-23 2024-01-24 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2022099117A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
WO2023278402A1 (en) * 2021-06-28 2023-01-05 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
KR20240046498A (ko) * 2021-08-09 2024-04-09 제넨테크, 인크. Brm의 조절에 사용하기 위한 페놀 유도체
AU2023269778A1 (en) * 2022-05-10 2024-12-12 Prelude Therapeutics Incorporated 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer
CA3252644A1 (en) * 2022-05-10 2023-11-16 Foghorn Therapeutics Inc. PYRAZINE DERIVATIVES AND THEIR USES
WO2024064316A1 (en) * 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024064328A1 (en) * 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
CN120152970A (zh) * 2022-10-03 2025-06-13 普莱鲁德疗法有限公司 使用smarca2降解剂和kras靶向疗法的组合实现的癌症治疗
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders
WO2025076357A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with taxane anticancer agent
US20250114353A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination Treatment Regimens - SMARCA2 Degrader With Gemcitabine
US20250114354A1 (en) 2023-10-04 2025-04-10 Prelude Therapeutics Incorporated Combination treatment regimens - smarca2 degrader with pd-1 inhibitors
WO2025106482A1 (en) * 2023-11-13 2025-05-22 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as smarca2/4 degraders and uses thereof
US20250276074A1 (en) 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
CN119638700B (zh) * 2024-11-01 2025-11-14 中科中山药物创新研究院 一种nsd2降解剂及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
BR112019015312A2 (pt) 2017-01-26 2020-03-10 Arvinas Operations, Inc. Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
US20190300521A1 (en) * 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2020251974A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US20230072658A1 (en) 2019-06-10 2023-03-09 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020251969A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) * 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
EP4081308A4 (en) * 2019-12-23 2024-01-24 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2022099117A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use

Also Published As

Publication number Publication date
CA3185888A1 (en) 2021-12-16
EP4161935A1 (en) 2023-04-12
JP2023529908A (ja) 2023-07-12
FI4161935T3 (fi) 2025-08-19
BR112022025061A2 (pt) 2023-01-31
PL4161935T3 (pl) 2025-09-08
EP4570319A3 (en) 2025-08-20
US11702423B2 (en) 2023-07-18
IL298933B1 (en) 2026-04-01
PT4161935T (pt) 2025-08-14
EP4570319A2 (en) 2025-06-18
EP4161935B1 (en) 2025-05-21
IL298933A (en) 2023-02-01
DK4161935T3 (da) 2025-08-18
US20240018158A1 (en) 2024-01-18
AU2021289730A8 (en) 2023-02-02
US20220033409A1 (en) 2022-02-03
MX2022015732A (es) 2023-02-13
ES3034380T3 (en) 2025-08-18
CN115867554B (zh) 2025-09-02
CN115867554A (zh) 2023-03-28
AU2021289730A1 (en) 2023-01-19
WO2021252666A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
CN115867554B (zh) Brm靶向化合物和相关使用方法
KR20230171979A (ko) Bcl6 단백질 분해의 조절제 및 관련 사용 방법
KR20230117577A (ko) Brm을 표적으로 하는 화합물 및 연관된 사용 방법
IL317676A (en) Heteroarylaminopyrimidine amides as autophagy inhibitors and methods of using them
KR20250011136A (ko) 암의 치료를 위한 smarca4 단백질 분해제로서의 6,6a,7,8,9,10-헥사하이드로-5h-피라지노[1',2':4,5]피라지노[2,3-c]피리다진 유도체
AU2021242143B2 (en) Aminopyrimidine derivatives and their use as Aryl hydrocarbon receptor modulators
US20240261418A1 (en) Sos1 degrading agent and preparation method therefor and application thereof
KR20250107915A (ko) Brm 표적화 화합물 및 연관된 사용 방법
CA3251489A1 (en) BCL-XL HETEROBFUNCTIONAL TETRAHYDROISOQUINOLINE DEGRADING AGENTS
KR20250036135A (ko) 유비퀴틴 리가제 결합 모이어티를 갖는 kat6 표적화 화합물
US20240336612A1 (en) BRM Targeting Compounds And Associated Methods Of Use
HK40128204A (en) Brm targeting compounds and associated methods of use
EA048707B1 (ru) Brm направленные соединения и связанные способы применения
EA050840B1 (ru) Brm направленные соединения и связанные способы применения
WO2025117881A1 (en) Compounds and methods for inhibiting autophagy
US20250161289A1 (en) KAT6 Targeting Compounds
CA2989684A1 (en) Hpk1 inhibitors and methods of using same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902